Posted by Two Blokes
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilit
Source: Two Blokes Trading
Posted by Two Blokes
BrightSpring boosts 2025 guidance as Pharmacy and Provider segments post strong gains and margin initiatives t
Source: Two Blokes Trading
Posted by Two Blokes
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development per
Source: Two Blokes Trading
Posted by Two Blokes
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impact
Source: Two Blokes Trading
Posted by Two Blokes
Paychex (PAYX) was the worst-performing stock in the S&P 500 Wednesday after the payroll and human resources s
Source: Two Blokes Trading
Posted by Two Blokes
Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pip
Source: Two Blokes Trading
Posted by Two Blokes
Tesla's new car sales plummeted 27.9% in May from the year before, according to data from the European Automob
Source: Two Blokes Trading
Posted by Two Blokes
Sales of new single-family homes dropped 13.7% in May compared with April, according to the U.S. Census. Home
Source: Two Blokes Trading
Posted by Two Blokes
Anterix Inc. (NASDAQ:ATEX ) Q4 2025 Earnings Call June 25, 2025 9:00 AM ET Company Participants Christopher Gu
Source: Two Blokes Trading
Posted by Two Blokes
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Styl
Source: Two Blokes Trading
Posted by Two Blokes
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Styl
Source: Two Blokes Trading
Posted by Two Blokes
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Styl
Source: Two Blokes Trading